Eli Lilly Partners with Twist Bioscience on AI Drug Discovery Data
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
What happened
Eli Lilly and Company formed a strategic partnership with Twist Bioscience Corporation regarding data provision and services. Under this arrangement, services are provided for TuneLab, Eli Lilly's artificial intelligence-driven drug discovery platform. Twist Bioscience will supply antibody characterization data, high-throughput wet-lab data, and support for AbLab, an antibody developability prediction model.
From yahoo.com
Why it matters
The collaboration allows users of Eli Lilly's TuneLab platform to order services from Twist Bioscience using preferred protocols. This partnership gives Eli Lilly an opportunity to participate in the growing AI-enabled drug discovery ecosystem as a provider of experimental data and services.
From yahoo.com
Who's involved
- Eli Lilly and CompanyAmerican pharmaceutical company involved in the strategic partnership.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Eli Lilly and CompanySpeculative
Eli Lilly and Company could benefit from potential incremental service revenue if adoption of its platforms leads to greater demand for antibody characterization and experimental services.
Keep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly and Novo Nordisk are pushing for claims-level patient data submission.
- Eli Lilly and Company plans to acquire Merida Biosciences for up to $2.8 billion in cash.
- Soutrik Banerjee is currently employed as a consultant at Eli Lilly and Company.
- Eli Lilly announced multiple new partnerships, including expanding Zepbound access with CVS Health, collaborating with Insilico Medicine, and investing in an AI lab with NVIDIA.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.